Salvo Gloria, Meyer Larissa A, Gonzales Naomi R, Frumovitz Michael, Hillman R Tyler
The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center, Department of Gynecologic Oncology and Reproductive Medicine, Houston, TX, USA.
Int J Gynecol Cancer. 2025 Mar;35(3):101639. doi: 10.1016/j.ijgc.2025.101639. Epub 2025 Jan 11.
Neuroendocrine cervical carcinomas are rare, aggressive tumors with a high risk of early metastasis and poor survival outcomes. Despite existing therapies, over half of patients experience recurrence or progression after primary treatment, and survival after recurrence remains limited. Survival rates have not significantly improved over the past several decades, underscoring an urgent need for better therapeutic options. The rarity of neuroendocrine cervical carcinoma has precluded randomized trials, leaving treatment strategies to be guided by small retrospective studies or adapted from protocols for small cell lung cancer. However, as we gain a deeper understanding of its unique origin, genomic landscape, and biological characteristics, it has become clear that neuroendocrine cervical carcinoma requires distinct management strategies. Key questions in managing neuroendocrine cervical carcinoma remain unanswered: does adjuvant radiation therapy improve outcomes for early-stage disease? Should neoadjuvant chemotherapy be considered for patients with bulky, localized tumors? Can immunotherapy improve outcomes when added to chemoradiation in locally advanced cases? Should immunotherapy be a standard option for recurrent disease? Addressing these questions requires a thorough understanding of the unique molecular and biological characteristics of neuroendocrine cervical carcinoma and its clinical behavior. This review aims to provide an updated summary of the molecular landscape of neuroendocrine cervical carcinoma, highlighting features that distinguish it from small cell lung cancer and align with other types of cervical cancer. We discuss current treatment approaches, identify gaps in knowledge, and examine paradigm-shifting clinical trials that have significantly impacted survival outcomes in cervical cancer and small cell lung cancer, translating these insights into potential strategies for neuroendocrine cervical carcinoma. By focusing on the unique aspects of neuroendocrine cervical carcinoma, this review emphasizes the need for specialized treatment strategies for this challenging disease.
神经内分泌宫颈癌是一种罕见的侵袭性肿瘤,具有早期转移风险高和生存预后差的特点。尽管现有治疗方法,但超过一半的患者在初始治疗后会出现复发或进展,复发后的生存率仍然有限。在过去几十年中,生存率并未显著提高,这凸显了对更好治疗选择的迫切需求。神经内分泌宫颈癌的罕见性使得随机试验难以开展,治疗策略只能由小型回顾性研究指导,或借鉴小细胞肺癌的治疗方案。然而,随着我们对其独特起源、基因组格局和生物学特性有了更深入的了解,很明显神经内分泌宫颈癌需要独特的管理策略。神经内分泌宫颈癌管理中的关键问题仍未得到解答:辅助放疗能否改善早期疾病的预后?对于肿瘤体积大、局限的患者,是否应考虑新辅助化疗?在局部晚期病例中,免疫治疗与放化疗联合使用能否改善预后?免疫治疗是否应成为复发性疾病的标准选择?解决这些问题需要全面了解神经内分泌宫颈癌独特的分子和生物学特性及其临床行为。本综述旨在提供神经内分泌宫颈癌分子格局的最新总结,突出其与小细胞肺癌的区别以及与其他类型宫颈癌的相似之处。我们讨论了当前的治疗方法,找出知识空白,并审视了对宫颈癌和小细胞肺癌生存结果产生重大影响的范式转变临床试验,将这些见解转化为神经内分泌宫颈癌的潜在策略。通过关注神经内分泌宫颈癌的独特方面,本综述强调了针对这种具有挑战性的疾病制定专门治疗策略的必要性。